Recent studies of QSAR on inhibitors of estrogen receptor and human eosinophil phosphodiesterase

Current Computer-Aided Drug Design

Volumn 5, Issue 3, 2009, Pages 200-214

  Xiang, Yuhong ^a   Zhang, Zhuoyong ^a   Xiao, Aijing ^a   Huo, Jinxu ^a  

^a CAPITAL NORMAL UNIVERSITY   (China)

Author keywords

Active conformation; Alignment rules; CoMFA; CoMSIA; HQSAR; Human eosinophil phosphodiesterase (PDE4); Inhibitors of estrogen receptor

Indexed keywords

COMPUTATIONAL CHEMISTRY; DISEASES; ESTERS; MOLECULAR GRAPHICS; MOLECULES;

ACTIVE CONFORMATION; ALIGNMENT RULE; COMFA; COMSIA; ESTROGEN RECEPTOR; HQSAR; HUMAN EOSINOPHILE PHOSPHODIESTERASE (PDE4); INHIBITOR OF ESTROGEN RECEPTOR; PHOSPHODIESTERASES; QUANTITATIVE STRUCTURE ACTIVITY RELATIONSHIP;

CONFORMATIONS;

1,4 DIHYDROPYRIDINE DERIVATIVE; 3 ARYLQUINAZOLINETHIONE DERIVATIVE; 5,6 DIHYDRO (9H) PYRAZOLO[3,4 C] 1,2,4 TRIAZOLO [4,3 ALPHA]PYRIDINE DERIVATIVE; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HEPARIN BINDING EPIDERMAL GROWTH FACTOR INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PROTEIN INHIBITOR; PROTEINASE INHIBITOR; SELECTIVE ESTROGEN RECEPTOR MODULATOR; UNCLASSIFIED DRUG;

ANALYTIC METHOD; BIOLOGICAL ACTIVITY; BREAST CANCER; COMPARATIVE MOLECULAR FIELD ANALYSIS; COMPARATIVE MOLECULAR SIMILARITY INDICES ANALYSIS; COMPUTER AIDED DESIGN; COMPUTER PROGRAM; DRUG DESIGN; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; HOLOGRAM QUANTITATIVE STRUCTURE ACTIVITY RELATION; HUMAN; HYDROGEN BOND; IC 50; INTERMETHOD COMPARISON; MOLECULAR MECHANICS; MOLECULAR MODEL; OSTEOPOROSIS; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW;

EID: 70350017834     PISSN: 15734099     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340909789054702     Document Type: Review

References (124)

1. Bucinski, A.; Markuszewski, M.J.; Wiktorowicz, W.; Krysinski, J.; Kaliszan, R. Artificial neural networks for prediction of antibacterial activity in series of imidazole derivatives. Comb. Chem. High Throughput Screen., 2004, 7, 327-336.
2. Buyukbingol, E.; Sisman, A.; Akyildiz, M.; Alparslan, F.N.; Adejare, A. Adaptive neuro-fuzzy inference system (ANFIS): a new approach to predictive modeling in QSAR applications: a study of neuro-fuzzy modeling of PCP-based NMDA receptor antagonists. Bioorg. Med. Chem., 2007, 15, 4265-4282.
3. Votano, J.R.; Parham, M.; Hall, L.M.; Hall, L.H.; Kier, L.B.; Oloff, S.; Tropsha, A. QSAR modeling of human serum protein binding with several modeling techniques utilizing structure-information representation. J. Med. Chem., 2006, 49, 7169-7181.
4. Votano, J.R.; Parham, M.; Hall, L.H.; Kier, L.B. New predictors for several ADME/Tox properties: aqueous solubility, human oral absorption, and Ames genotoxicity using topological descriptors. Mol. Divers., 2004, 8, 379-391.
5. Jalali-Heravi, M.; Asadollahi-Baboli, M.; Shahbazikhah, P. QSAR study of heparanase inhibitors activity using artificial neural networks and Levenberg-Marquardt algorithm. Eur. J. Med. Chem., 2008, 43, 548-556.
6. Szaleniec, M.; Witko, M.; Tadeusiewicz, R.; Goclon, J. Application of artificial neural networks and DFT-based parameters for prediction of reaction kinetics of ethylbenzene dehydrogenase. J. Comput. Aided Mol. Des., 2006, 20, 145-157.
7. Liu, G.; Yu, J. QSAR analysis of soil sorption coefficients for polar organic chemicals: substituted anilines and phenols. Water Res., 200 5, 39, 2048-2055.
8. Hemmateenejad, B.; Safarpour, M.A.; Miri, R.; Taghavi, F. Application of ab initio theory to QSAR study of 1,4-dihydropyridine-based calcium channel blockers using GA-MLR and PC-GA-ANN procedures. J. Comput. Chem., 2004, 25, 1495-1503.
9. Lu, Q.; Shen, G.; Yu, R. Genetic training of network using chaos concept: application to QSAR studies of vibration modes of tetrahedral halides. J. Comput. Chem., 2002, 23, 1357-1365.
10. Siu, F.M.; Che, C.M. Quantitative structure-activity (affinity) relationship (QSAR) study on protonation and cationization of alpha-amino acids. J. Phys. Chem. A., 2006, 110, 12348-12354.
11. Zahouily, M.; Lazar, M.; Elmakssoudi, A.; Rakik, J.; Elaychi, S.; Rayadh, A. QSAR for anti-malarial activity of 2-aziridinyl and 2,3-bis(aziridinyl)-1,4-naphthoquinonyl sulfonate and acylate derivatives. J. Mol. Model., 2006, 12, 398-405.
12. Hasegawa, K.; Funatsu, K. Partial least squares modeling and genetic algorithm optimization in quantitative structure-activity relationships. SAR QSAR Environ. Res., 2000, 11, 189-209.
13. Deeb, O.; Hemmateenejad, B. ANN-QSAR model of drug-binding to human serum albumin. Chem. Biol. Drug Des., 2007, 70, 19-29.
14. Liu, H.; Papa, E.; Walker, J.D.; Gramatica, P. In silico screening of estrogen-like chemicals based on different nonlinear classification models. J. Mol. Graph. Model., 2007, 26, 135-144.
15. Sparks, T.C.; Crouse, G.D.; Dripps, J.E.; Anzeveno, P.; Martynow, J.; Deamicis, C.V.; Gifford, J. Neural network-based QSAR and insecticide discovery: spinetoram. J. Comput. Aided Mol. Des., 2008, 22, 393-401.
16. Niu, B.; Lu, W.C.; Yang, S.S.; Cai, Y.D.; Li, G.Z. Support vector machine for SAR/QSAR of phenethyl-amines. Acta Pharmacol. Sin., 2007, 28, 1075-1086.
17. Fatemi, M.H.; Gharaghani, S. A novel QSAR model for prediction of apoptosis-inducing activity of 4-aryl-4-H-chromenes based on support vector machine. Bioorg. Med. Chem., 2007, 15, 7746-7754.
18. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110, 5959-5967.
19. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Recent advances in comparative molecular field analysis (CoMFA). Prog. Clin. Biol. Res., 1989, 291, 161-165.
20. Du, Q.S.; Huang, R.B.; Chou, K.C. Recent advances in QSAR and their applications in predicting the activities of chemical molecules, peptides and proteins for drug design. Curr. Protein Pept. Sci., 2008, 9, 248-260.
21. Cao, H.; Cao, R.; Zhang, H.; Zheng, X.; Gao, D. Non-nucleoside inhibitors of NS5B polymerase binding to allosteric sites: 3D-QSAR and molecular docking studies. Curr. Med. Chem., 2008, 15, 1462-1477.
22. Wei, H.Y.; Lu, C.S.; Lin, T.H. Exploring the P2 and P3 ligand binding features for hepatitis C virus NS3 protease using some 3D QSAR techniques. J. Mol. Graph. Model., 2008, 26, 1131-1144.
23. Klebe, G.; Mietzner, T.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity. J. Med. Chem., 1994, 37, 4130-4146.
24. Caballero, J.; Fernández, M.; González-Nilo, F.D. Structural requirements of pyrido[2,3-d]pyrimidin-7-one as CDK4/D inhibitors: 2D autocorrelation, CoMFA and CoMSIA analyses. Bioorg. Med. Chem., 2008, 16, 6103-6115.
25. Wei, H.Y.; Tsai, K.C.; Lin, T.H. Modeling ligand-receptor interaction for some MHC class II HLA-DR4 peptide mimetic inhibitors using several molecular docking and 3D QSAR techniques. J. Chem. Inf. Model., 2005, 45, 1343-1351.
26. Evans, D.A.; Doman, T.N.; Thorner, D.A.; Bodkin, M.J. 3D QSAR methods: phase and catalyst compared. J. Chem. Inf. Model., 2007, 47, 1248-1257.
27. Hopfinger, A.J.; Tokarski, J.S.; Tokarski, J.S.; Jin, B.; Albuquerque, M.; Madhav, P.J.; Duraiswami, C. Construction of 3D-QSAR models using the 4D-QSAR analysis formalism. J. Am. Chem. Soc., 1997, 119, 10509-10524.
28. Vedani, A.; Briem, H.; Dobler, M.; Dollinger, H.; McMasters, D.R. Multiple-conformation and protonation-state representation in 4D-QSAR: the neurokinin-1 receptor system. J. Med. Chem., 2000, 43, 4416-4427.
29. Lukacova, V.; Balaz, S. Multimode ligand binding in receptor site modeling: implementation in CoMFA. J. Chem. Inf. Comput. Sci., 2003, 43, 2093-2105.
30. Vedani, A.; Dobler, M.; Lill, M.A. Combining protein modeling and 6D-QSAR. Simulating the binding of structurally diverse ligands to the estrogen receptor. J. Med. Chem., 2005, 48, 3700-3703.
31. Vedani, A.; Dobler, M.; Dollinger, H.; Hasselbach, K.M.; Birke, F.; Lill, M.A. Novel ligands for the chemokine receptor-3 (CCR3): A receptor-modeling study based on 5D-QSAR. J. Med. Chem., 2005, 48, 1515-1527.
32. Lill, M.A. Multi-dimensional QSAR in drug discovery. Drug Discov. Today, 2007, 12, 1013-1017.
33. Xiao, A.J.; Zhang, Z.Y.; An, L.Y.; Xiang, Y.H. 3D-QSAR and docking studies of 3-arylquinazolinethione derivatives as selective estrogen receptor modulators. J. Mol. Model., 2008, 14, 149-159.
34. Huo, J.X.; Zhang, Z.Y.; Xiao, A.J.; Xiang, Y.H. QSAR Study of a Series of 5,6-Dihydro-(9H)-pyrazolo[3,4-c]-1,2,4 -triazolo[4,3-a]pyridine Inhibitors by CoMFA. Comput. Appl. Chem., 2009, 26, 171-174.
35. Huo, J.X.; Zhang, Z.Y.; Xiao A.J.; Xiang, Y.H. HQSAR study of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α] pyridine inhibitors. Chem. Res. Appl., In press.
36. Robinson-Rechavi, M.; Escriva, G.H.; Laudet, V. The nuclear receptor superfamily. J. Cell. Sci., 2003, 116, 585-586.
37. Güngör, T.; Chen, Y.; Golla, R.; Ma, Z.; Corte, J.R.; Northrop, J.P.; Bin, B.; Dickson, J.K.; Stouch, T.; Zhou, R.; Johnson, S.E.; Seethala, R.; Feyen, J.H. Synthesis and characterization of 3-arylquinazolinone and 3-arylquinazolinone derivatives as selective estrogen receptor beta modulators. J. Med. Chem., 2006, 49, 2440-2455.
38. Duplantier, A.J.; Bachert, E.L. SAR of a series of 5,6-dihydro-(9H)-pyrazolo [3,4-c]-1,2,4-triazolo[4,3-a]pyridines as potent inhibitors of human eosinophil phosphodiesterase. J. Med. Chem., 2007, 50, 344-349.
39. Tang, H.F.; Chen, J.Q.; Xie, Q.M.; Zheng, X.Y.; Zhu, Y.L.; Adcock, I.; Wang, X. The role of PDE4 in pulmonary inflammation and goblet cell hyperplasia in allergic rats. Biochim. Biophys. Acta, 2006, 1762, 525-532.
40. Parkkonen, J.; Hasala, H.; Moilanen, E.; Giembycz, M.A.; Kankaanranta, H. Phosphodiesterase 4 inhibitors delay human eosinophil and neutrophil apoptosis in the absence and presence of salbutamol. Pulm. Pharmacol. Ther., 2008, 21, 499-506.
41. Cramer, R.D.; Milne, M. The Lattice Model: A general paradigm for shape-related structure/activity correlation. Abstracts ACS Meeting, 1979, COMP 44.
42. Wold, S.; Ruhe, A.; Wold, H.; Dunn, W.J. The collinearity problem in linear regression. the partial least squares (PLS) approach to generalized inverses. SIAM J. Sci. Stat.Comput., 1984, 5, 735-743.
43. Labrie, P.; Maddaford, S.P.; Fortin, S.; Rakhit, S.; Kotra, L.P.; Gaudreault, R. A comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of anthranilamide derivatives that are multidrug resistance modulators. J. Med. Chem., 2006, 49, 7646-7660.
44. Langer, T.; Hoffmann, R.D. On the use of chemical function-based alignments as input for 3D-QSAR. J. Chem. Inf. Comput. Sci., 1998, 38, 325-330.
45. Zhang, Z.Y.; An, L.Y.; Hu, W.X.; Xiang, Y.H. 3D-QSAR study of hallucinogenic phenylalkylamines by using CoMFA approach. J. Comput. Aided Mol. Des., 2007, 21, 145-153.
46. Jiang, H.L.; Chen, K.X.; Tang, Y.; Chen, J.; Li, Q.; Wang, Q.M.; Ji, R.Y. Molecular modeling and 3D-QSAR studies on the interaction mechanism of tripeptidyl thrombin inhibitors with human r-thrombin. J. Med. Chem., 1997, 40, 3085-3090.
47. Hariprasad, V.; Kulkarni, V.M. A proposed common spatial pharmacophore and the corresponding active conformations of some peptide leukotriene receptor antagonists. J. Comput. Aided Mol. Des., 1996, 10, 284-292.
48. Debnath, A.K. Comparative molecular field analysis (CoMFA) of a series of symmetrical bis-Benzamide cyclic urea derivatives as HIV-1 protease inhibitors. J. Chem. Inf. Comput. Sci., 1998, 38, 761-767.
49. Cui, M.; Huang, X.Q.; Luo, X.M.; Briggs, J.M.; Ji, R.Y.; Chen, K.X.; Shen, J.H.; Jiang H.L. Molecular docking and 3D-QSAR studies on gag peptide analogue inhibitors interacting with human cyclophilin A. J. Med. Chem., 2002, 45, 5249-5259.
50. Bhongade, B.A.; Gadad, A.K. 3D-QSAR CoMFA/CoMSIA studies on Urokinase plasminogen activator (uPA) inhibitors: a strategic design in novel anticancer agents. Bioorg. Med. Chem., 2004, 12, 2797-2805.
51. Sharma, P.C.; Sharma, S.V.; Sharma A.; Suresh B. 3D-QSAR CoMFA study of some heteroarylpyrroles as possible anticandida agents. Indian J. Pharm. Sci., 2008, 70, 154-158.
52. Dixit, A.; Kashaw, S.K.; Gaur, S.; Saxena, A.K. Development of CoMFA, advance CoMFA and CoMSIA models in pyrroloquinazolines as thrombin receptor antagonist. Bioorg. Med. Chem., 2004, 12, 3591-3598.
53. Wei, D.G.; Yang, G.F.; Wan, J.; Zhan, C.G. Binding model construction of antifungal 2-Aryl-4-chromanones. J. Agric. Food Chem., 2005, 53, 1604-1611.
54. Jayatilleke, P.R.; Nair, A.C.; Zauhar, R.; Welsh, W.J. Computational studies on HIV-1 protease inhibitors: influence of calculated inhibitor-enzyme binding affinities on the statistical quality of 3D-QSAR CoMFA models. J. Med. Chem., 2000, 43, 4446-4451.
55. Kulkarni, S.S.; Kulkarni, V.M. Three-dimensional quantitative structure-activity relationship of interleukin 1-β converting enzyme inhibitors: A comparative molecular field analysis study. J. Med. Chem., 1999, 42, 373-380.
56. Gokhale, V.M.; Kulkarni, V.M. Comparative molecular field analysis of fungal squalene epoxidase inhibitors. J. Med. Chem., 1999, 42, 5348-5358.
57. Tafi, A.; Anastassopoulou, J.; Theophanides, T.; Botta, M.; Corelli, F.S.; Massa, A.M.; Costi, R.; Santo, R.D.; Ragno, R. Molecular modeling of azole antifungal agents active against Candida albicans. 1. a comparative molecular field analysis study. J. Med. Chem., 1996, 39, 1227-1235.
58. Rathi, L.; Kashaw, S.K.; Dixit, A.; Pandey, G.; Saxena, A.K. Pharmacophore identification and 3D-QSAR studies in N-(2-benzoyl phenyl)-L-tyrosines as PPARγ agonists. Bioorg. Med. Chem., 2004, 12, 63-69.
59. http://www.netsci.org/Science/Compchem/feature09.html
60. Talele, T.T.; Kulkarni, S.S.; Kulkarni, V.M. Development of pharmacophore alignment models as input for comparative molecular field analysis of a diverse set of azole antifungal agents. J. Chem. Inf. Comput. Sci., 1999, 39, 958-966.
61. Shi, L.M.; Fang, H.; Tong, W.D.; Wu, J.; Perkins, R.; Blair, R.M.; Branham, W.S.; Dial, S.L.; Moland, C.L.; Sheehan, D.M. QSAR models using a large diverse set of estrogens. J. Chem. Inf. Comput. Sci., 2001, 41, 186-195.
62. Kulkarni, S.S., Newman, A.H.; Houlihan, W.J. Three-dimensional quantitative structure-activity relationships of mazindol analogues at the dopamine transporter. J. Med. Chem., 2002, 45, 4119-4127.
63. Yu, S.J.; Keenan, S.M.; Tong, W.; Welsh, W.J. Influence of the structural diversity of data sets on the statistical quality of three-dimensional quantitative structure-activity relationship (3D-QSAR) models: predicting the estrogenic activity of xenoestrogens. Chem. Res. Toxicol., 2002, 15, 1229-1234.
64. Juvale, D.C.; Kulkarni, V.V.; Deokar, H.S.; Wagh, N.K.; Padhye, S.B.; Kulkarni, V.M. 3D-QSAR of histone deacetylase inhibitors: hydroxamate analogues. Org. Biomol. Chem., 2006, 4, 2858-2868.
65. Samee, W.; Ungwitayatorn, J.; Matayatsuk, C.; Pimthon, J. 3D-QSAR studies on phthalimide derivatives as HIV-1 reverse transcriptase inhibitors. ScienceAsia, 2004, 30, 81-88.
66. Morris, G.M.; Goodsell, D.S.; Halliday, R.S.; Huey, R.; Hart, W.E.; Belew, R.K.; Olson, A.J. Automated docking using a lamarckian genetic algorithm and empirical binding free energy function. J. Comput. Chem., 1998, 19, 1639-1662.
67. http://www.ccdc.ac.uk/prods/gold.html
68. Rarey, M.; Kramer, B.; Lengauer, T.; Klebe, G. A fast flexible docking method using an incremental construction algorithm. J. Mol. Biol., 1996, 261, 470-489.
69. Jain, A.N. Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search. J. Comput. Aided Mol. Des., 2007, 21, 281-306.
70. Khedkar, S.A.; Malde, A.K.; Coutinho, E.C. Design of inhibitors of the murF enzyme of streptococcus pneumoniae using docking, 3D-QSAR, and de novo design. J. Chem. Inf. Model., 2007, 47, 1839-1846.
71. Zaheer-ul, H.; Uddin, R.; Yuan, H.; Petukhov, P.A.; Choudhary, M.I.; Madura, J. D. Receptor-based modeling and 3D-QSAR for a quantitative production of the butyrylcholinesterase inhibitors based on genetic algorithm. J. Chem. Inf. Model., 2008, 48, 1092-1103.
72. Kharkar, P.S.; Desai, B.; Gaveria, H.; Varu, B.; Loriya, R.; Naliapara, Y.; Shah, A.; Kulkarni, V.M. Three-dimensional quantitative structure-activity relationship of 1,4-Dihydropyridines as anti-tubercular agents. J. Med. Chem., 2002, 45, 4858-4867.
73. 8-THC analogues: relationship of side-chain conformation to cannabinoid receptor affinity and pharmacological potency. J. Med. Chem., 2000, 43, 59-70.
74. Bursi, R.; Sawa, M.; Hiramatsu, Y.; Kondo, H. A three-dimensional quantitative structure-activity relationship study of heparin-binding epidermal growth factor shedding inhibitors using comparative molecular field analysis. J. Med. Chem., 2002, 45, 781-788.
75. Sipila, J.; Taskinen, J. CoMFA modeling of human catechol O-Methyltransferase enzyme kinetics, J. Chem. Inf. Comput. Sci., 2004, 44, 97-104.
76. Bush, B.L.; Nachbar, R.B. Sample-distance partial least-squares PLS optimized for many variables, with application to CoMFA. J. Comput.-Aided Mol. Des., 1993, 7, 587-619.
77. Peng, H.; Wang, T.; Xie, P.; Chen, T.; He, H.W.; Wan, J. Molecular docking and three-dimensional quantitative structure-activity relationship studies on the binding modes of herbicidal 1-(Substituted Phenoxyacetoxy) alkylphosphonates to the E1 component of pyruvate dehydrogenase. J. Agric. Food Chem., 2007, 55, 1871-1880.
78. Durst, G.L. Comparative molecular field analysis (CoMFA) of herbicidal protoporphyrinogen oxidase inhibitors using standard steric and electrostatic fields and an alternative LUMO field. Quant. Struct.-Act. Relat., 1998, 17, 419-426.
79. Eriksson, L.; Johansson, E.; Müller, M.; Wold, S. On the selection of the training set in environmental QSAR analysis when compounds are clustered. J. Chemo., 2000, 14, 599-616.
80. Lowis, D.R. HQSAR: a new highly predictive QSAR technique. Tripos Technol. Notes, 1997, 1, 1-7.
81. Kulkarni, S.S.; Patel, M.R.; Talele, T.T. CoMFA and HQSAR studies on 6,7-dimethoxy-4-pyrrolidylquinazoline derivatives as phosphodiesterase10A inhibitors. Bioorg. Med. Chem., 2008, 16, 3675-3686.
82. Freitas, R.F.; Oprea, T.I.; Montanari, C.A. 2D QSAR and similarity studies on cruzain inhibitors aimed at improving selectivity over cathepsin L. Bioorg. Med. Chem., 2008, 16, 838-853.
83. Salum, L.B.; Polikarpov, I.; Andricopulo, A.D. Quantitative structure-activity relationships for a series of selective estrogen receptor-beta modulators. SAR. QSAR Environ. Res., 2007, 18, 711-727.
84. Honorio, K.M.; Garratt, R.C.; Andricopulo, A.D. Hologram quantitative structure -activity relationships for a series of farnesoid X receptor activators. Bioorg. Med. Chem. Lett., 2005, 15, 3119-3125.
85. Doddareddy, M.R.; Lee, Y.J.; Cho, Y.S.; Choi, K.I.; Koh, H.Y.; Pae, A.N. Hologram quantitative structure activity relationship studies on 5-HT6 antagonists. Bioorg. Med. Chem., 2004, 12, 3815-3824.
86. Honorio, K.M.; Garratt, R.C.; Andricopulo, A.D. Hologram quantitative structure-activity relationships for a series of farnesoid X receptor activators. Bioorg. Med. Chem. Lett., 2005, 15, 3119-3125.
87. Ashek, A.; San Juan, A.A.; Cho, S.J. HQSAR study of betaketoacyl-acyl carrier protein synthase III (FabH) inhibitors. J. Enzyme Inhib. Med. Chem., 2007, 22, 7-14.
88. Moda, T.L.; Montanari, C.A.; Andricopulo, A.D. Hologram QSAR model for the prediction of human oral bioavailability. Bioorg. Med. Chem., 2007, 15, 7738-7745.
89. Huang, H.; Wang, X.D.; Dai, X.L.; Yu, Y.J.; Wang, L.S. Holographic quantitative structure-activity relationship for prediction acute toxicity of benzene derivatives to the guppy (Poecilia reticulata). J. Environ. Sci., 2004, 16, 423-427.
90. Cui, S.; Wang, X.; Liu, S.; Wang, L. Predicting toxicity of benzene derivatives by molecular hologram derived quantitative structure-activity relationships (QSARs). SAR QSAR Environ. Res., 2003, 14, 223-231.
91. Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M.J. Cancer statistics. CA Cancer J. Clin., 2008, 58, 71-96.
92. Thomas, T.; Gallo, M.A.; Thomas, T.J. Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases. Curr. Cancer Drug Targets, 2004, 4, 483-499.
93. Musa, M.A.; Cooperwood, J.S.; Khan, M.O. A review of coumarin derivatives in pharmacotherapy of breast cancer. Curr. Med. Chem., 2008, 15, 2664-2679.
94. Sommer, S.; Fuqua, S.A. Estrogen receptor and breast cancer. Semin. Cancer Biol., 2001, 11, 339-352.
95. Lee, W.L.; Cheng, M.H.; Chao, H.T.; Wang, P.H. The role of selective estrogen receptor modulators on breast cancer: from tamoxifen to raloxifene. Taiwan J. Obstet. Gynecol., 2008, 47, 24-31.
96. Swaby, R.F.; Sharma, C.G.; Jordan, V.C. SERMs for the treatment and prevention of breast cancer. Rev. Endocr. Metab. Disord., 2007, 8, 229-239.
97. Kallen, J.; Lattmann, R.; Beerli, R.; Blechschmidt, A.; Blommers, M.J.; Geiser, M.; Ottl, J.; Schlaeppi, J.M.; Strauss, A.; Fournier, B. Crystal structure of human estrogen-related receptor alpha in complex with a synthetic inverse agonist reveals its novel molecular mechanism. J. Biol. Chem., 2007, 282, 23231-23239.
98. Kuiper, G.G.; Enmark, E.; Pelto-Huikko, M.; Nilsson, S.; Gustafsson, J.A. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. USA, 1996, 93, 5925-5930.
99. Dechering, K.; Boersma, C.; Mosselman, S. Estrogen receptors alpha and beta: two receptors of a kind? Curr. Med. Chem., 2000, 7, 561-576.
100. Barrett, I.; Meegan, M.J.; Hughes, R.B.; Carr, M.; Knox, A.J.; Artemenko, N.; Golfis, G.; Zisterer, D.M.; Lloyd, D.G. Synthesis, biological evaluation, structural-activity relationship, and docking study for a series of benzoxepin-derived estrogen receptor modulators. Bioorg. Med. Chem., 2008, 16, 9554-9573.
101. Bentrem, D.J.; Jordan, V.C. Targeted antiestrogens for the prevention of breast cancer. Oncol. Res., 1999, 11, 401-407.
102. Howell, S.J.; Johnston, S.R.; Howell, A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract. Res. Clin. Endocrinol. Metab., 2004, 18, 47-66.
103. Manson, M.M.; Farmer, P.B.; Gescher, A.; Steward, W.P. Innovative agents in cancer prevention. Recent Results. Cancer Res., 2005, 166, 257-275.
104. Agatonovic-Kustrin, S.; Turner, J.V.; Glass, B.D. Molecular structural characteristics as determinants of estrogen receptor selectivity. J. Pharm. Biomed. Anal., 2008, 48, 369-375.
105. Salum, L.B.; Polikarpov, I.; Andricopulo, A.D. Structural and chemical basis for enhanced affinity and potency for a large series of estrogen receptor ligands: 2D and 3D QSAR studies. J. Mol. Graph. Model., 2007, 26, 434-442.
106. Wolohan, P.; Reichert, D.E. CoMFA and docking study of novel estrogen receptor subtype selective ligands. J. Comput. Aided Mol. Des., 2003, 17, 313-328.
107. Salum, L.B.; Polikarpov, I.; Andricopulo, A.D. Structure-based approach for the study of estrogen receptor binding affinity and subtype selectivity. J. chem. Inf. Model., 2008, 48, 2243-2253.
108. Yang, X.S.; Wang, X.D.; Ji, L.; Li, R.; Sun, C.; Wang, L.S. Combining docking and comparative molecular similarity indices analysis (COMSIA) to predict estrogen activity and probe molecular mechanisms of estrogen activity for estrogen compounds. Chin. Sci. Bull., 2008, 53, 3626-3633.
109. Gao, H., Katzenellenbogen, J.A.; Garg, R.; Hansch, C. Comparative QSAR analysis of estrogen receptor ligands. Chem. Rev., 1999, 99, 723-744.
110. Steiner, A.A.; Antunes-Rodrigues, J.; Branco, L.G.S. Role of preoptic second messenger systems (cAMP and cGMP) in the febrile response. Brain Res., 2002, 944, 135-145.
111. Kammer, G.M. The adenylate cyclase-cAMP-protein kinase A pathway and regulation of the immune response. Immunol. Today, 1988, 9, 222-229.
112. Ravipati, G.; McClung, J.A.; Aronow, W.S.; Peterson, S.J.; Frishman, W.H. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol. Rev., 2007, 15, 76-86.
113. Boswell-Smith, V.; Spina, D.; Page, C.P. Phosphodiesterase inhibitors. Br. J. Pharmacol., 2006, 147, S252-S257.
114. Chung K.F. Phosphodiesterase inhibitors in airways diseases. Eur. J. Pharmacol., 2006, 533, 110-117.
115. Krymskaya, V.P.; Panettieri, R.A. Jr. Phosphodiesterases regulate airway smooth muscle function in health and disease. Curr. Top Dev. Biol., 2007, 79, 61-74.
116. Dent, G.; Poppe, H.; Egerland, J.; Marx, D.; Szelenyi, I.; Branscheid, D.; Magnussen, H.; Rabe, K.F. Effects of a selective PDE4 inhibitor, D-22888, on human airways and eosinophils in vitro and late phase allergic pulmonary eosinophilia in guinea pigs. Pulm. Pharmacol. Ther., 1998, 11, 13-21.
117. Jeffery, P. Phosphodiesterase 4-selective inhibition: novel therapy for the inflammation of COPD. Pulm. Pharmacol. Ther., 2005, 18, 9-17.
118. Spina, D. The potential of PDE4 inhibitors in respiratory disease. Curr. Drug Targets Inflamm. Allergy, 2004, 3, 231-236.
119. Kang, N.S.; Jhon, D.J.; Song, J.H.; Yoo, S.E. Docking and 3-D QSAR studies of dual PDE4-PDE7 inhibitors. Mol. Simulat., 2007, 33, 1109-1117.
120. Yang, Z.Q.; Sun, P.H. 3D-QSAR study of Potent Inhibitor of Phosphodiesterase-4 by using CoMFA approach. Int. J. Mol. Sci., 2007, 8, 714-722.
121. Chakraborti, A.K.; Gopalakrishnan, B.; Sobhia, M.E.; Malde, A. 3D-QSAR studies on thieno[3,2-d]pyrimidines as phosphodiesterase IV inhibitors. Bioorg. Med. Chem. Lett., 2003, 13, 1403-1408.
122. Ducrot, P.; Andrianjara, C.R.; Wrigglesworth, R. CoMFA and CoMSIA 3D-quantitative structure-activity relationship model on benzodiazepine derivatives, inhibitors of phosphodiesterase IV. J. Comput. Aided Mol. Des., 2001, 15, 767-785.
123. Sheng, C.Q.; Zhang, W.N.; Ji, H.T.; Zhang, M.; Song, Y.L.; Xu, H.; Zhu, J.; Miao, Z.Y.; Jiang, Q.F.; Yao, J.Z.; Zhou, Y.J.; Zhu, J.; Lu J.G. Structure-based optimization of azole antifungal agents by CoMFA, CoMSIA, and molecular docking. J. Med. Chem., 2006, 49, 2512-2525.
124. Salama, I.; Schlotter, K.; Utz, W.; Hübner, H.; Gmeiner P.; Boeckler F. CoMFA and CoMSIA investigations of dopamine D3 receptor ligands leading to the prediction, synthesis, and evaluation of rigidized FAUC 365 analogues. Bioorg. Med. Chem., 2006, 14, 5898-5912.